We aimed to develop a risk model, based on single-nucleotide polymorphism (SNP) markers associated with an increased risk of organ-specific GVHD in 394 transplant pairs. A total of 259 SNPs were genotyped in 53 genes and evaluated for their associated risk of organ-specific GVHD. Risk models were generated using both clinical factors and genetic SNP markers. Patients were stratified by quartiles according to their risk scores and then categorized into three groups (low, intermediate and high risk) according to this model. We compared the risk of overall and organ-specific GVHD amongst these groups. Several SNP markers in the cytokine-, apoptosis-, TGF-b-and PDGF-mediated pathways were identified as correlative markers of acute and chronic GVHD. Each organspecific GVHD shared some common biologic pathway such as cytokine, TGF-b-or PDGF-mediated pathways. However, we also identified different SNP markers that correlated with increased risk of organ-specific GVHD (for example, FCGR2A SNP for oral GVHD, and FAS and TGFB1 SNP for lung GVHD). The incorporation of genetic risk factors into the clinical factors risk model improved stratification power for organ-specific GVHD. The SNP-based approach was suggested to improve risk stratification of organ-specific GVHD.
INTRODUCTION
GVHD is a clinical syndrome that presents with heterogeneous and diverse clinical manifestation. Acute GVHD can develop in the liver, gut or skin. Chronic GVHD can involve the mouth, eyes, liver, lung and gut. Recently, the National Institutes of Health (NIH) developed a system to classify GVHD into acute classical, acute late-onset, overlapping or chronic classical GVHD. 1 This system classifies the subtypes of GVHD according to their classical presentation. However, there is still significant heterogeneity in the clinical presentation of GVHD. For instance, some patients may only present with chronic lung GVHD, whereas others may present with severe chronic oral and eye GVHD without any lung involvement. It is evident that there are different underlying mechanisms provoking for clinical manifestations of GVHD in each organ.
The pathogenesis of GVHD is not yet fully understood. Alloreactive T lymphocytes are known as key mediators in the development of GVHD. Alloreactive T cells induce activation of other immune cells that attack target organs, resulting in tissue inflammation. 2, 3 Although this has been accepted as the major mechanism in the pathogenesis of GVHD (especially in acute GVHD), there is evidence that other immune mechanisms such as humoral immunity involving B cells are involved. 4 Furthermore, it is not clear if the same pathogenic processes mediate the development of GVHD in every target organ.
We hypothesized that organ-specific GVHD has distinctive underlying biologic pathways. Therefore, the concept of organspecific GVHD was used in this study in order to perform separate analyses of GVHD risk for each organ.
In our previous study, we adopted a SNP-based risk model to predict clinical outcomes following allogeneic hematopoietic SCT (HSCT) 5 and found that this approach can improve prognostic stratification of patients. The aim of this study was to identify potential SNP markers associated with increased risk of organspecific GVHD by analyzing 259 SNPs in 53 genes potentially involved in the pathogenesis of GVHD.
MATERIALS AND METHODS

Patient and transplantation characteristics
The study population consisted of 394 consecutive patients who underwent HSCT at the Princess Margaret Hospital (PMH), Toronto, ON, Canada, and their respective donors. The Research Ethics Board at the PMH, University Health Network, Toronto, ON, Canada approved this study. The clinical characteristics of the patients are described in Table 1 .
In terms of overall transplant outcomes, the incidences of grade 2-4, grade 1-4 acute GVHD at day 100 and chronic GVHD at 2 years were 67.2±2.5%, 82.1±2.1% and 87.8±2.2%, respectively. The incidence of organ-specific acute GVHD at day 100 was 66.4±2.5% for skin, 35.9±2.5% for gut and 34.5±2.9% for liver, while that of organ-specific chronic GVHD at 2 years was 69.8 ± 3.1% for skin, 30.3 ± 3.2% for eye, 55.8 ± 3.3% for mouth, 21.2 ± 2.8% for lung and 67.3 ± 3.0% for liver, respectively.
Selection of multiple SNP panel
A total of 259 SNPs were genotyped for 53 genes as shown in the Supplementary Table 1. The candidate genotypes were selected based on the current literature in 2006 at the time of inception of this study. If SNP information was not available in the literature, SNPs were selected using the criteria of nonsynonymous SNP in exon with minor allele frequency 1 45%. The list of selected SNPs and their biologic pathways is as follows: cytokine-mediated pathway (IL1A and IL1B and their receptors, IL1R1, IL2 &  IL2RA, IL4 & IL4R, IL6 & IL6R, IL8, IL10 & IL10RA/RB, IL12A/B and IL12RB1, IFNG  & IFNGR1/ 23 
Sequenom MassARRAY Genotyping System
Genotyping was performed with the Sequenom iPLEX platform, according to the manufacturer's instructions (www.sequenom.com; Sequenom Inc, San Diego, CA, USA). 24 Whole-blood samples were obtained according to the declaration of Helsinki, before HSCT from both recipients and donors. DNA was extracted using the Puregene DNA purification kit (Gentra Systems Inc, Minneapolis, MN, USA), and SNPs were detected by analyzing primer extension products generated from previously amplified genomic DNA using a Sequenom chip-based matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectrometry platform. Multiplex SNP assays were designed using SpectroDesigner software (Sequenom). Ninety-six-well plates were used to PCR amplify DNA (2.5 ng per well) according to Sequenom protocols. Unincorporated nucleotides were deactivated using shrimp alkaline phosphatase, and allele discrimination reactions were conducted after addition of the extension primer(s), DNA polymerase and a cocktail mixture of deoxynucleotide triphosphates and dideoxynucleotide triphosphates to each well. MassExtend clean resin (Sequenom) was added to the mixture to remove extraneous salts that could interfere with MALDI-TOF analysis. The primer extension products were then cleaned and spotted onto a SpectroChip. Genotypes were determined by spotting an aliquot of each sample onto a 384 SpectroChip (Sequenom), which was subsequently read by the MALDI-TOF mass spectrometer. Duplicate samples and negative controls were included to assure genotyping quality. Primer sequences are available in the Supplementary Table 2 .
Definition of statistical end points
The day of the stem cell infusion was defined as day 0. Acute and chronic GVHD were diagnosed and graded using established criteria. 25, 26 Acute GVHD was evaluated only up to day 100. The incidence of GVHD was calculated from day 0 to the day it was diagnosed. 25, 26 The incidence of organ-specific GVHD was defined as the first day of clinical manifestation and/or diagnosis in each organ including skin, liver or gut for acute GVHD and skin, eye, mouth, lung or liver for chronic GVHD regardless of other organ involvement.
Statistical analysis
An overview of the study is summarized in Figure 1 . The patient clinical characteristics and transplant outcomes are presented in Table 1 . The incidences of acute and chronic GVHD and organ-specific GVHD were estimated using the cumulative incidence method considering competing risks. 27 In addition, the incidence of acute GVHD grade 2-4 was also calculated because it was generally accepted as clinically significant GVHD requiring systemic steroid therapy. Genotype and allele frequencies are summarized in the Supplementary Tables 1A and B. Hardy-Weinberg equilibrium was also tested to confirm that there is no statistical deviation of genotype frequency using Haploview version 3.32 (Broad Institute, SNPs predictive of organ-specific GVHD D Kim et al Cambridge, MA, USA; available at http://www.broad.mit.edu/mpg/haploview). 28 Statistics were also performed using SAS version 9.1 (SAS institute, Cary, NC, USA) and the R package (http://CRAN.R-project.org).
Univariable analyses. A total of 259 SNPs were compared using genetic additive, dominant and recessive models with respect to the risk of overall acute and chronic GVHD and organ-specific GVHD. The P-values using additive models are presented in the Supplementary Tables 3A and 3B. Considering that this study is exploratory and hypothesis generating, statistical tests were two-sided with a significance level of 0.01.
Multivariable analyses. After identifying potential SNPs (P-value o0.01), we performed multivariable models adjusting for clinic risk factors. Cox proportional hazard regression models were constructed for the time to event outcomes of acute, chronic GVHD and organ-specific GVHD as well as grade 2-4 acute GVHD. Covariates for GVHD were as follows: donor status (HLA-matched related donor vs others); stem cell source (BM vs PBSC); age (o50 years vs X50 years); disease risk (high risk vs standard risk); and conditioning regimen (myeloablative vs reduced intensity). A stepwise selection algorithm was applied for model selection using the criteria for variable selection, P ¼ 0.05 for variable entry and P ¼ 0.1 for variable removal. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the significant risk factors, based on a multivariable analysis with a statistical significance level of 0.05.
Generation of risk models. As our previous study demonstrated successful application of a SNP-based risk model for the prediction of post-transplant outcomes, 5 we calculated a risk score to predict the event hazard (calculated in multivariable analyses) compared with that of baseline risk based on significant genetic and/or clinical factors found in univariable and multivariable analyses for each time-to-event end point. The risk score was defined as a weighted sum of the significant risk factors, where the weights were the estimated log-hazard ratios.
For each outcome, we stratified patients into quartiles and divided them into three groups: low risk (first quartile [Q1]); intermediate risk (the second and third quartiles [Q2-3]); and high risk (the fourth quartile [Q4]). We then compared the risk of organ-specific GVHD according to these three risk groups using Gray's test. Tests of association between the outcome and risk groups were assessed according to P-value and HR. A C-statistic is the probability that predicting an outcome is better than chance with values ranging from 0.50 (no predictive ability) to 1.00 (perfect predictive ability). We calculated a C-statistic for each model to determine the predictive effects of the categorized risk groups. We also compared the predictive ability of the models using C-statistics, a measure of how frequently a group without event has a lower predicted probability of event compared with those already having event. The model with higher C-statistics infers higher predictability of the event. P-values were calculated comparing the C-statistics of different models.
Stratification power of the risk models. Finally, in order to compare the stratification power of the risk model generated using the clinical and genetic factors with that using clinical factors alone, we performed a C-statistic analysis for each transplant outcome in a pooled population (n ¼ 394). We used the likelihood ratio tests to compare the C-statistics between two models using R (rcorrp.cens function).
RESULTS
Genotype frequencies in the overall population A total of 259 SNPs were evaluated in the cytokine pathways (n ¼ 118), NFKB (n ¼ 29), apoptosis (n ¼ 17), endothelium nitric oxide regulation (n ¼ 17), PDGF (n ¼ 22), TGF-b (n ¼ 22), Toll-like receptor (n ¼ 14), NOD2/CARD15 (n ¼ 10), prostaglandin-endoperoxide synthase (n ¼ 9) and FCGR2A (n ¼ 1). Detailed genotypes and allele frequencies for the 259 SNPs are summarized in Supplementary Table 1 .
Of the 259 SNP markers, 10 were monomorphic in our study cohort: PTGS2 (rs20426), IL1B (rs3087261), TGFBR2 (34833812), IL6 (rs3087226), NOS3 (rs41377046 and rs41508746), IKK1 (rs17881084), NOD2/CARD15 (rs34684955), NFKBIB (rs3136643) and PDGFB (rs RS33925758). These 10 SNPs were excluded from the analysis.
Identification of potential SNP markers associated with higher risk of acute/chronic GVHD and organ-specific GVHD in univariate analyses As shown in the Figure 2 , details of the results are presented as Manhattan plots presenting -log10 (P-value) of the SNPs. In summary, the following potential associations of genotypes with GVHD were identified: for overall acute GVHD, recipient FAS (rs2234978 and rs2862833), EDN1 (rs4714384), TGFB1 (rs1800469), NFKBIA (rs2233409), NOS1 (rs9658258), and donor TNFRII (rs3397 and rs945439), TLR5 (rs851182); for acute GVHD grade 2-4, recipient EDN1 (rs4714384), NOS1 (rs9658258), and donor TNFRII (rs3397), TLR5 (rs851182), IL2 (rs11575810); for overall chronic GVHD, donor IL1R1 (rs2110726 and rs3917225) and FCRG2A (rs1801274). Further details of the associations between transplant outcomes and the 259 SNPs are presented in Supplementary  Table 3A and B.
When SNP markers were analyzed for their associated risk with organ-specific GVHD, some risk patterns emerged. In summary, the risk of acute skin GVHD was associated with recipient PDGFD (rs10895534) and donor NOS2A (rs3730017), TNFRII (rs3397) and TGFB1 (rs1800469); acute liver GVHD with recipient PDGFRB (rs2302273) and IFNGR1 (rs2234711), and donor PTGS1 (rs10306114), NOS1 (rs9658254) and IL1R1 (rs2192752); acute gut GVHD with recipient IL4 (rs2243248) and donor PDGFD (rs1053861), TGFBR1 (rs420549 and rs868) and IL12A (rs2243115); chronic skin GVHD with recipient PDGFC (rs1425486; Supplementary Figure 1 ) and donor NFKBA (rs1805034; Supplementary Figure 1) , PDGFC (rs1425486 and rs1425485) and NOS2A (rs3730017); chronic eye GVHD with recipient IL6R (rs4845617), IL10RB (rs8178561), and PDGFRB (rs2229562; Supplementary Figure 1) , and donor TGFBR1 (rs868; Supplementary Figure 1) ; chronic oral GVHD with recipient IL12RB1 (rs3746190 and rs11575926) and donor FCRG2A (rs1801274); and chronic lung GVHD with recipient TGFB2 (rs7550232), TGFB1 (rs1800469; Supplementary Figure 1) , FAS (rs9325604; Supplementary Figure 1) , and RelB (rs10856) and donor TGFB2 (rs7550232), IL4R (rs2057768), FAS (rs1468063 and rs2234767), TGFB1 (rs1800469) and IL12B (rs3181226). No SNPs were found to be associated with chronic liver GVHD.
Potential SNP markers associated with higher risk of organ-specific GVHD in multivariable models Multivariable analyses were performed to confirm that statistically significant SNP markers identified in the univariable analysis were independent of the clinical factors. Table 2 summarizes the result of multivariable analysis for risk factors of acute and chronic GVHD. In the analysis, as described in the Methods, several clinical factors as well as significant SNPs in univariable analyses (Po0.01) were included. The risk of overall acute GVHD was associated with clinical factors such as donor status and conditioning intensity. In addition, recipient FAS genotype (rs2234978), EDN1 genotype (rs4714384) and TGFB genotype (rs1800469), and donor TNFRII genotype (rs3397) were also associated with for the risk of acute GVHD (Table 2 ). Significant risk factors for overall chronic GVHD were the source of stem cells, a previous episode of acute GVHD, the donor IL1R1 (rs3917225) and FCGR2A genotype (rs1801274).
As presented in the Table 2 , multivariable analyses showed several SNP markers could predict the risk of organ-specific acute GVHD in combination with clinical factors. Recipient PDGFD (rs10895534), donor NOS2A (rs3730017), TNFRII (rs3397) and TGFB1 (rs1800469) genotypes were associated with the risk of acute skin GVHD, in combination with the clinical factor, donor status. For the risk of acute liver or gut GVHD, several SNP markers were found to be risk factors of acute liver GVHD; recipient PDGFRB (rs2302273), IFNGR1 (rs2234711) and donor PTGS1 (rs10306114), NOS2 (rs9658254), IL1R1 (rs2192752) genotypes and the risk of acute gut GVHD; recipient IL4 (rs2243248), donor PDGFD (rs1053861), TGFBR1 (rs420549), IL12A (rs2243115) genotypes (Supplementary Figure 2) . Of note, there was no overlap in the SNP marker profiles associating with the risk of acute GVHD in each organ.
Two clinical risk factors were associated with organ-specific chronic GVHD with statistical significance. These were source of stem cells and a preceding episode of acute GVHD as shown in the Table 2 . Two SNPs were found to be associated with an increased risk of overall chronic GVHD including (rs3917225) on donor IL1R1 and FCGR2A genotype (rs1801274) (Supplementary Figure 2) . However, several additional SNP markers were found to be associated with the risk of organ-specific chronic GVHD (Supplementary Figure 2) . The risk of chronic eye GVHD was associated with recipient IL10RB (rs8178561), PDGFRB (rs22229562), IL6R (rs4845617), and donor TGFBR1 (rs868). The risk of chronic lung GVHD was associated with recipient TGFB2 (rs3746190), and donor IL4R (rs2057768), FAS (rs2234767), IL12B (rs3181226) and TGFB1 (rs1800469); chronic oral GVHD with IL12RB1 (rs3746190) and donor FCGR2A (rs1801274). As was the case in acute organ-specific GVHD, there was no overlap among the SNP marker profiles that predict the risk of each organ-specific chronic GVHD. For instance, the FCGR2A genotype seemed to be very unique to chronic oral GVHD, whereas the FAS and TGFB1 genotypes were strongly associated with the risk of chronic lung GVHD. This suggests that different biologic pathways are involved in the development of GVHD in different organs.
Generation of GVHD risk models that include both clinical factors and genetic SNP markers
We then calculated risk scores based on the results from the multivariable analyses, and these were weighted by the size of the effect on the HR ( Table 2) . The final models calculating risk scores are summarized in the Supplementary Table 4 . Then patient scores were stratified into quartiles for each outcome and these were categorized into three groups: low risk (the first quartile [Q1]); moderate risk (the second and third quartiles [Q2-3]); and high risk (the fourth quartile [Q4]).
As shown in Figure 2 , the risk model could stratify patients according to their risk of overall acute GVHD (Po0.001), overall chronic GVHD (Po0.001) and of each organ-specific chronic GVHD (Figure 2 and Supplementary Table 5 and 6); Po0.001 for chronic skin GVHD, Po0.001 for chronic eye GVHD, Po0.001 for chronic oral GVHD and Po0.001 for chronic lung GVHD. 
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Comparison of the risk stratification powers of GVHD risk models generated by clinical and genetic factors vs clinical factors alone We compared the risk stratification power of the risk models generated by clinical and genetic factors to that generated using clinical factors alone ( Table 3 ). The incorporation of the SNP markers into the risk models increased the C-statistics by 0.079 (mean, range 0.032-0.142) ( Table 3 ). In the risk models of overall acute and chronic GVHD, risk stratification power was improved by 3.2% and 3.5%, respectively, based on C statistics. In organspecific acute GVHD, risk stratification power was improved by 10.8%, 14.2% and 8.8% for acute skin, liver and gut GVHD, respectively. Also, it was also improved by 8.0, 13.6 and 7.1% for chronic skin, eye and oral GVHD. The likelihood ratio tests confirmed that the improvement of risk stratification power is significantly improved by incorporation of the SNP markers into the risk models (Table 3 ). This finding implies that the addition of SNP markers to the clinical risk model provides better discrimination of patients at high risk of organ-specific GVHD.
DISCUSSION
This study demonstrates that (1) SNP markers can predict the risks of acute and chronic GVHD and of organ-specific GVHD; (2) the concept of 'organ-specific GVHD' is useful in developing more precise GVHD risk models because different biologic pathways may be involved in GVHD in different organs; (3) there appear to be common biologic pathways in the pathogenesis of acute GVHD such as TGFB-, and TNFR-mediated pathways but certain biologic Abbreviations: 95% CI ¼ 95% confidence interval; aGVHD ¼ acute graft-versus-host disease; cGVHD ¼ chronic graft-versus-host disease; HR ¼ hazard ratio; MAC ¼ myeloablative conditioning; MRD ¼ HLA-matched related donor; RIC ¼ reduced intensity conditioning.
SNPs predictive of organ-specific GVHD D Kim et al marker risk profiles are specific for each organ in both acute and chronic GVHD; (4) incorporating genetic risk factors into clinical risk factor-based models can improve their GVHD risk stratification power. Clinical presentations of GVHD are very heterogeneous, so we separated overall GVHD into organ-specific GVHD. A SNP-based genome-wide association study can explore unpredicted genetic risk factors. However, in order to detect significant SNP-based risk factors, a clear definition of a phenotype (that is, clinical diagnosis) is necessary. If we use a composite definition of GVHD (that is, overall GVHD), then a genome-wide SNP association study has a higher probability of missing significant markers even if a SNP marker has significant predictive power for a subset within the clinical phenotype (that is, organ-specific GVHD). Accordingly, we evaluated SNP markers for organ-specific GVHD.
Several SNP markers in the cytokine-mediated pathway were found to be associated with the risk of GVHD including TNFRII, IL1R1, IFNGR1, TGFB1, TGFBR1, IL4, IL4R, IL10RB, IL12A and IL12RB1. The cytokine-mediated pathway is known to be central in the development of GVHD. [29] [30] [31] In both acute and chronic GVHD, several cytokines and their receptors, including IL1, IL2, IFN-g, IL6, IL10, TNF and TGF-b, contribute to the development of GVHD. [6] [7] 9, [31] [32] [33] These cytokines are involved in the activation of alloreactive T lymphocytes 31 and in the interaction between alloreactive T cells and antigen-presenting cells. 34 Although the subject remains controversial, numerous studies have demonstrated a strong association of cytokine SNPs with the risk of acute and chronic GVHD. These include the IL1 gene family, IFN-g, IL6, IL10, the TNF family and its receptor (TNFRII), and TGFb. 6, 7, 9, 18, 23, [31] [32] [33] Our study similarly revealed cytokine SNPs that are significant predictors of the risk of GVHD, including the TGF-b mediated pathway (for overall acute GVHD, acute skin and gut GVHD, and chronic eye and lung GVHD), TNFRII (for acute skin GVHD), IFNG (for acute liver GVHD), IL1R1 (for overall chronic GVHD and acute liver GVHD), IL4 (for acute gut GVHD and chronic lung GVHD), IL10RB (for chronic eye GVHD) and IL12 (for acute gut GVHD, chronic oral and lung GVHD).
The incorporation of SNP markers into a risk model generated using clinical risk factors improved the model's risk stratification power. For example, the only consistent clinical risk factor for chronic overall, eye or oral GVHD was the source of stem cells. However, when we explored potential SNP markers, additional two, four and two SNP markers could predict the risk of overall, eye and oral chronic GVHD, respectively. Consequently, incorporation of these markers into the clinical model improved its stratification power by 3.5%, 13.6% and 7.1% for overall, eye and oral chronic GVHD, respectively (Table 3) . Chronic lung GVHD had no associated clinical risk factors, but we were able to identify SNP markers on the genes, IL4R, IL12B, FAS, TGFB1 and TGFB2, as risk factors (Table 2) .
Different SNP markers were found to correlate with the risk of organ-specific GVHD. This finding implies that different biologic pathways are involved in the pathogenesis of GVHD in different organs. For example, the FCGR2A gene SNP is unique to oral GVHD. The SNPs on the FAS and TGFB1 genes are specific to the risk of chronic lung GVHD. There are no animal models for chronic GVHD, which limits basic and translational research in its pathogenesis. Therefore, the approach used in this study maybe useful in the exploration of potential biologic pathways in organ-specific GVHD. There is a great need for further investigation into the roles of these genes in the pathogenesis of organ-specific GVHD.
Another important finding is the contribution of the PDGFmediated pathway to the development of GVHD, especially the cutaneous form. Stimulatory autoantibodies against the PDGF receptor (PDGFR) are frequently found in patients with either extensive chronic GVHD or the de novo form of systemic sclerosis. 16 Also, refractory sclerodermatous chronic GVHD and de novo scleroderma can be effectively treated with imatinib, a PDGFR blocker. 35 In this study we found strong associations between SNPs of PDGFC and chronic skin GVHD, PDGFD and acute skin and gut GVHD, and PDGFRB and acute liver GVHD. Further detailed investigations are needed to determine whether these SNPs are associated with the development of autoantibodies to PDGFR or cutaneous GVHD.
Apoptosis of the targeted tissue or alloreactive lymphocytes is both inevitable and necessary during the development of GVHD, especially of acute GVHD. 36 In acute GVHD, apoptosis is the predominant form of skin injury, 37, 38 although this is also observed in chronic GVHD. 3 FAS protein, an apoptosis-mediating surface Ag, has an important role in the pathogenesis of GVHD, 39 and we found a potential correlation between an FAS gene SNP and the risks of acute GVHD and chronic lung GVHD.
An interesting finding from this study is the potential involvement of NOS1 (nitric oxide synthase (1) in the development of GVHD. NOS1 is located on chromosome 12q24.2-q24.31 and regulates the production of nitric (NO), a reactive free radical involved in the inflammatory mechanism of target cell apoptosis and that has been shown to possess antimicrobial activities. Previous studies have suggested a protective role of nitric NO against GVHD. 13, 15 In our study, an NOS1 SNP was found to be associated with risk of lower OS, higher non-relapse mortality acute skin GVHD, acute liver GVHD and chronic skin GVHD. This suggests a potential association between the regulation of NO production and acute GVHD and HSCT outcomes.
The incidences of acute and chronic GVHD in this study were slightly higher than in other studies. However, the incidence of acute GVHD reported here is based on any grade of GVHD regardless of the requirement of systemic therapy. Alternative end point of grade 2-4 acute GVHD can be used, however, when the group is divided according to their requirement of systemic steroid therapy, somewhat heterogeneous subgroup of subclinical GVHD patients and another group not developing any GVHD will be treated as one group, which affects data analysis significantly with significant bias on control arm. Also, the question remains if grade 1 acute GVHD is real event of GVHD or from other etiologies other than GVHD.
In addition, the diagnosis of chronic GVHD was made using the revised Seattle criteria 25, 26 because study was initially designed in 2006 before the NIH consensus criteria of chronic GVHD diagnosis is widely used. Also, 70% of patients, mainly those with matched Abbreviations: aGVHD ¼ acute graft-versus-host disease; cGVHD ¼ chronic graft-versus-host disease. C-statistic comparisons of models with clinical factors alone and those with both clinical and genetic factors.
a Likelihood ratio tests were used to compare the C-statistics between two models using R (rcorrp.cens function).
SNPs predictive of organ-specific GVHD D Kim et al related donors, received PBSC and the remaining 30% who received marrow had unrelated donors, these factors probably increased the risk of chronic GVHD. The limitation of the present study is lack of external validation with an independent cohort. Thus, to consolidate the present risk model, further replication is strongly warranted to confirm current risk model especially including larger number of independent patients with different ethnicities.
There are several potential uses for these risk models in the treatment of transplant patients. Although this study requires further replication and validation, these risk models can be used to identify high-risk patients for organ-specific GVHD, allowing personalized prophylactic intervention. For example, for patients at high-risk of chronic lung GVHD, inhaled prophylactic corticosteroids with frequent monitoring of pulmonary function could be suggested. 40 CYA eye drops could be used in patients at high risk of chronic eye GVHD. 41, 42 On the basis of potential SNP markers found to be associated with organ-specific GVHD, functional animal studies could be undertaken to define the roles of these genes in the pathogenesis of GVHD.
In conclusion, risk models incorporating clinical and genetic factors enhance the stratification power of models predicting patient transplant outcomes and risk of GVHD. Our study suggests that the SNP-based approach can improve stratification of patients at high risk of organ-specific GVHD and that different SNP markers can predict the risk of GVHD in each organ more precisely.
